Given a graph and a source vertex in
the graph, find shortest paths from
source to all vertices in the given
graph. Dijkstra’s algorithm is very
similar to Prim’s algorithm for minimum
spanning tree. Like Prim’s MST, we
generate a SPT (shortest path tree)
with given source as root.
We maintain two sets, one set contains
vertices included in shortest path tree,
other set includes vertices not yet
included in shortest path tree. At every
step of the algorithm, we find a vertex
which is in the other set (set of not yet
included) and has a minimum distance from
the source. Below are the detailed steps
used in Dijkstra’s algorithm to find the
shortest path from a single source vertex
to all other vertices in the given graph.
Algorithm Create a set sptSet (shortest
path tree set) that keeps track of vertices
included in shortest path tree, i.e., whose
minimum distance from source is calculated
and finalized. Initially, this set is empty.
Assign a distance value to all vertices in
the input graph. Initialize all distance
values as INFINITE.
Assign distance value as 0 for the source
vertex so that it is picked first. While
sptSet doesn’t include all vertices Pick a
vertex u which is not there in sptSet and
has minimum distance value. Include u to
sptSet. Update distance value of all adjacent
vertices of u. To update the distance values,
iterate through all adjacent vertices. For
every adjacent vertex v, if sum of distance
value of u (from source) and weight of edge
u-v, is less than the distance value of v,
then update the distance value of v.
Given a graph and a source vertex in the
graph, find shortest paths from source to
all vertices in the given graph. Dijkstra’s
algorithm is very similar to Prim’s
algorithm for minimum spanning tree.
Like Prim’s MST, we generate a SPT (shortest
path tree) with given source as root.
We maintain two sets, one set contains
vertices included in shortest path tree,
other set includes vertices not yet included
in shortest path tree.
At every step of the algorithm, we find a
vertex which is in the other set (set of not
yet included) and has a minimum distance
from the source.
Below are the detailed steps used in
Dijkstra’s algorithm to find the shortest
path from a single source vertex to all other
vertices in the given graph. Algorithm
Create a set sptSet (shortest path tree set)
that keeps track of vertices included in
shortest path tree, i.e., whose minimum
distance from source is calculated and
finalized. Initially, this set is empty. Assign
a distance value to all vertices in the input
graph. Initialize all distance values as INFINITE.
Assign distance value as 0 for the source
vertex so that it is picked first. While sptSet
doesn’t include all vertices Pick a vertex u
which is not there in sptSet and has minimum
distance value. Include u to sptSet.
Update distance value of all adjacent vertices
of u. To update the distance values, iterate
through all adjacent vertices. For every
adjacent vertex v, if sum of distance value
of u (from source) and weight of edge u-v,
is less than the distance value of v, then
update the distance value of v.
• Protein
• Cell Line
• DNA
• mRNA
• Functional characterization
• Binding/Affinity/Specificity
• Antibody production
• In vitro functional assay
• Developability
• Affinity maturation
• Humanization
• Fc-Engineering
• Structure-Based Protein Design
• Target assessment
• Recombinant protein
• Recombinant cell-line
• Beacon® single B cell screening
• Display technology
• CAR-function based functional screening
• Hybridoma
• HCAb direct cloning screening
• TCR Mimic Antibody
• PK / PD
• Efficacy
• ADA
• TOX
• Stable cell line
• Process development
• Manufacture
Protein
Cell Line
DNA
mRNA
Functional characterization
Binding / Affinity
Antibody production
In vitro functional assay
Developability
Affinity maturation
Humanization
Fc-Engineering
Structure-Based Protein Design
Target assessment
Recombinant protein
Recombinant cell-line
Beacon® single B cell screening
Display technology
CAR-function based functional screening
Hybridoma
HCAb direct cloning screening
PK / PD
Efficacy
ADA
TOX
Stable cell line
Process development
Manufacture
Protein
Cell Line
DNA
mRNA
Functional characterization
Binding / Affinity
Antibody production
In vitro functional assay
Developability
Affinity maturation
Humanization
Fc-Engineering
Structure-Based Protein Design
Target assessment
Recombinant protein
Recombinant cell-line
Beacon® single B cell screening
Display technology
CAR-function based functional screening
Hybridoma
HCAb direct cloning screening
PK / PD
Efficacy
ADA
TOX
Stable cell line
Process development
Manufacture
Nona’s Comprehensive Capabilities
Leveraging the expertise at Nona Biosciences, we collaborate closely with our clients to customize the preparation of target immunogens, ensuring the development of ideal antibodies that align perfectly with our clients’ requirements. Our dedicated scientific team is skilled in preparing a variety of different types of immunogens, including target-expressing cell lines, recombinant proteins, mRNA-LNPs, plasmids, and peptides.
After decades of operation, Nona team has fine-tuned the immunization procedure to ensure the induction of a robust immune response against the target. Depending on the type of immunogen, the immunization route, frequency, and dose are carefully selected to increase the likelihood of obtaining a diverse range of antibodies.
Nona’s technology team has developed a range of powerful and innovative platforms to complement H2L2 and HCAb Harbour Mice®. These diverse platforms maximize the potential for screening lead antibodies that align with our clients’ specific requirements.
Nona’s experienced scientific team has developed a series of assays to comprehensively evaluate the antibody’s functions. Furthermore, we collaborate closely with our clients to establish target-specific assays, ensuring the finalization of the lead antibodies to meet their specific requirements.
In vivo studies serve as the bridge connecting basic research to clinical trials, representing one of the most critical aspects of therapeutic antibody development. The Nona team has meticulously established a range of animal models to validate the pharmacodynamics, therapeutic efficacies, immunogenicities, and toxicities of lead antibodies.
Our accomplished scientific team has effectively implemented both phage display and yeast display technology platforms for protein engineering. These platforms play a pivotal role in substantially elevating the development potential of lead antibodies.
To expedite the drug development process, Nona is proud to offer an extensive array of CMC services, including the development of stable cell lines and scalable process development, manufacturing, comprehensive product testing, and the preparation of CMC submission dossiers.
Beacon® single B cell screening
Display technology
CAR-function based functional screening
Hybridoma
HCAb direct cloning screening
TCR Mimic Antibody
Functional characterization
Binding / Affinity
Antibody production
In vitro functional assay
Developability
Protein
Cell line
DNA
mRNA
Target assessment
Recombinant protein
Recombinant cell-line
Affinity maturation ▶
Humanization▶
Fc-Engineering▶
Structure-Based Protein Design
▶
Stable cell line
Process development
Manufacture
PK / PD
Efficacy
ADA
TOX
Dr. Jingsong Wang is Chairman of Nona Biosciences. Prior to that, Dr. Wang served as Head of China R&D and Head of Translational Medicine, Asia Pacific, at Sanofi. He is a former attending physician and clinical fellow at Harvard Medical School. Dr. Wang received his Ph.D. in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher’s laboratory at the Harvard School of Public Health.
Dr. Yiping Rong is our Chief Scientific Officer. He is a well-recognized scientist with about 20 years’ experience of biomedical research and drug discovery. Dr. Rong used to work at Sanofi, JNJ and Roche and built strong expertise in cancer biology and pharmacology. He led and contributed to >15 programs entering clinical trials. He is also involved in translational research work for a few drugs. Multiple mAb or bispecific antibodies generated from his team were out licensed to MNCs. Some highly innovative first-in-class projects are in clinical trials. He worked on apoptosis, epigenetics, immuno-oncology, and cancer cell signaling fields and led the drug discovery projects including kinase, enzyme, receptor/ligand, protein-protein-interaction targets by small molecules or monoclonal antibodies. Dr. Rong received his Ph.D. degree in Pharmacology from Case Western Reserve University (Cleveland, Ohio). He is the member of American Association of Cancer Research and has more than twenty publications in cancer research field, including Nature Genetics, Molecular Cell, PNAS papers. He is also the inventor of dozens of patents in drug discovery field.
Dr. Jiyong Zhang leads business development at Nona Biosciences, bringing vision and dedication to strategic growth and client satisfaction. With 15 years of experience in biotherapeutic research and development, Dr. Zhang’s understanding of market dynamics and ability to identify mission-aligned opportunities are evident.
Before overseeing business development at Nona, Dr. Zhang played key roles at Alexion and Abbvie, contributing to antibody discovery, engineering, and bispecific antibody R&D. His scientific experiences and knowledge in biotherapeutic innovation makes him a forward-thinking strategist focused on enhancing service offerings to meet evolving client needs.
With Dr. Zhang and his team driving business development, Nona Biosciences is poised to offer innovative solutions and unparalleled service. This solidifies the company’s position as a trusted and client-focused drug discovery partner in the dynamic landscape of biotherapeutic innovation.
Dr. Joe Zhao is Vice President and Head of External Innovation of Nona Biosciences. Joe holds a BS from Fudan University and a PhD from University of Delaware, followed by postdoctoral trainings at Lankenau Medical Center and Zeneca Pharmaceuticals. Prior to joining Harbour BioMed, he was in small biotechs (Pharmacopeia and Ligand Pharmaceuticals) and large MNC (BMS). Joe has 25 years of combined experience in drug discovery of both small molecules and biologics in therapeutic areas of immuno-oncology, immunology, and genetic diseases.
Mr. Louis Liu is Senior Vice President and Head of Scientific Operation of Nona Biosciences. He graduated from Bethune Medical University with Bachelor Degree of Medicine. He has over 30 years’ experience in antibody technology platform establishment, antibody discovery and discovery team management experience. Previously he worked in Syntron Bioresearch Inc as R&D manager, Strategic Diagnostic Inc as product development supervisor, Rockland Immunochemical Inc as Manager of Monoclonal Antibody service and product development, GenScript Ltd as vice president of Antibody Division, Shanghai ChemPartner as vice president of Biologics Discovery.
Dr. Yun He is Chief Technology Officer of Nona Biosciences. Before Nona Biosciences spun off from Harbour BioMed, Dr. He served as Head of Antibody Technology at Harbour BioMed. During his tenure there, Dr. He contributed to multiple discovery programs and led the team in establishing HBICE® platform. Prior to joining Harbour BioMed, Dr. He was an Investigator at Biologics Center in Novartis, where he was responsible for antibody engineering and bioinformatics. Prior to that, Dr. He was the group leader of Bioinformatics at GenScript. Dr. He received his Ph.D. from the Chinese Academy of Sciences, with a focus on molecular biology and bioinformatics.
Dr. Musheng Bao earned his Ph.D. in China and completed his postdoctoral training at MD Anderson Cancer Center and Baylor Institute for Immunology Research. Beginning his professional journey as a Scientist II at MedImmune, Dr. Bao later transitioned to Sanofi, where he served as a Principal Scientist. Following this, he joined Harbour BioMed, where he led a team dedicated to therapeutic antibody development utilizing the Harbour Mice® platform. Presently, Dr. Bao has taken on the role of Head of Biology at Nona Biosciences.
Dr. Arkinstall has demonstrated remarkable competence throughout his career. He is a respected leader in drug discovery with substantial roles under his belt, including Research Head, Chief Scientific Officer (CSO), and Chief Executive Officer (CEO) positions at various pharmaceutical or biotech companies. Dr. Arkinstall served as CEO of Elstar Therapeutics and Revitope Oncology, companies advancing novel classes of multi-specific antibody-based cancer drugs. He previously was also the CSO of Kymab, an antibody therapeutics company founded in Cambridge, UK, prior to which he spent 16 years in progressively senior research leadership roles at EMD (Merck) Serono, and its associated entities across Europe and the United States.
Dr. Grosveld is Co-founder and CSO of Harbour Antibodies and the inventor of Harbour Mice®, Professor and former Head of Department of Cell Biology and Department of Clinical Genetics at Erasmus University Medical Center, Rotterdam, a fellow of Royal Society and a member of Royal Netherlands Academy of Arts and Sciences. Dr. Grosveld’s research on the control of globin gene expression has been selected as one of the top ten achievements of Medical Research Council (UK) (MRC) in the 20th century by Higher Education and Research Opportunities in the U.K. Dr. Grosveld was awarded the Louis-Jeantet Prize for Medicine in 1991, the Spinozapremie (Spinoza Prize) in 1995.
Dr. Kamen is a Venture Partner at Third Rock Ventures. In 2005, he co-founded BioAssets Development Corporation and served as its Chairman. He currently serves as an independent non-executive Director of Harbour BioMed and a director of Jounce Therapeutics (NASDAQ:JNCE). He was previously a director of Neon Therapeutics and Harbour Antibodies. Earlier in his career, he was senior vice president of scientific affairs at the pioneering biotechnology firm named Genetics Institute, Inc. Dr. Kamen received his bachelor’s degree in biophysics from Amherst College, a Ph.D. in biochemistry and molecular biology from Harvard University Graduate School of Arts and Sciences. During his academic scientific career, he worked at the Imperial Cancer Research Fund.
Dr. Kramer serves as CSO of Portage Biotech Inc. Dr. Kramer previously served as Vice President and Head of Discovery for Oncology Therapeutics at Janssen Research & Development, LLC (the Pharmaceutical Division of Johnson and Johnson), where he was responsible for leading Global Discovery, focusing on aberrant signaling cascades in tumor cells, as well as epigenetic reprogramming and tumor immunology using both small molecule and protein-based large molecule approaches. Prior to joining Janssen Research & Development, LLC, Dr. Kramer served as VP Drug Discovery and Research for Bristol-Myers Squibb (BMS), where he provided scientific leadership and strategic oversight for many pre-clinical Oncology and Immunology programs and projects that entered development. Dr. Kramer was previously an Assistant Professor at Harvard Medical School. Dr. Kramer received his Ph.D. in pharmacology from the University of Vermont and completed his post-doctoral fellowship in Oncology at the National Cancer Institute, National Institutes of Health.
Peter Moesta, Ph.D., oversaw the development, production and worldwide launch of important medicines, such as Humira, Yervoy and Opdivo. Dr. Moesta previously served in executive roles at Bristol-Myers Squibb.
Dr. Tian is an academician of Chinese Academy of Engineering, a member of Academia Europaea and a medical immunologist. Currently, he is a professor at University of Science and Technology of China (USTC), where he also works as Dean at School of Basic Medical Sciences, and Director at Institute of Immunology. He is also the Director of the Key Lab of Innate Immunity and Chronic Diseases of Chinese Academy of Science.
Dr. Tian was awarded with the National Science Fund for Distinguished Young Scholars. He is the academic leader of Chang Jiang Scholars Program as well as the Innovation Research Program of National Natural Science Foundation of China. Dr. Tian is Head of National Science and Technology Major Project and Chief Scientist of National Major Research Plan Program.
Dr. Tian’s laboratory is credited with seminal discoveries regarding basic knowledge and clinical study of natural killer (NK) cells, particularly liver-resident NK cells, cytokine-producing NK cells, and NK cell-based immunotherapy.
